Tissue Inhibitors of Matrix Metalloproteinase-3, Potential Therapeutic Target against Multiple Sclerosis

1Amir Ghaemi, 2Kasra Hamdi, 3Mansoureh Togha, 4,5Hadi Kazemi and 6Ali Gorji
1Department of Microbiology, School of Medicine, Infectious Diseases Research Centre, Golestan University of Medical Sciences, Gorgan, Iran
2Department of Microbiology, Tehran Sciences and Research Branch of IAU, Tehran, Iran
3Young Researchers Club, Science and Research Branch, Islamic Azad University, Tehran, Iran
4Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran
5Shefa Neuroscience Research Center, Tehran, Iran
6Department of Pediatric, Shahed University, Tehran, Iran
7Institut für Physiologie I, Westfälische Wilhelms-Universität Munster, Robert-Koch-Strasse Munster, Germany

Corresponding Author: Amir Ghaemi, Department of Microbiology and Virology, Golestan University of Medical Sciences and Health Care, P.O. Box 49175-1141, Gorgan, Iran. Tel: +98714421651, +9871444025

ABSTRACT

The Matrix Metalloproteinase Proteins (MMPs) comprise a large group of endoproteinases that cleave most, if not all, components of the extracellular matrix. The activities of MMPs are modulated by manipulation in the levels of natural MMP inhibitors, the “Tissue Inhibitors of Metalloproteinases” (TIMPs). In a pathological processes of Multiple Sclerosis (MS), the MMP-2 and 9 (Gelatinase) are over expressed and balance of TIMP and MMP expression is perturbed, leading to locally increased proteolytic activity of Gelatinase and uncontrolled degradation of the Blood Brain Barrier (BBB) and myelin basic protein. Therefore, Gelatinase are the main mediators in the evolution of MS and TIMP has been proposed as a novel therapeutic target for MS therapy.

Key words: Multiple sclerosis, matrix metallo proteinase proteins, tissue inhibitors of metalloproteinases, therapeutic target

INTRODUCTION

Matrix Metallo Proteinases (MMPs), naturally occurring superfamily of endoproteinases, are composed of at least 26 members of zinc-containing enzymes produced by many cell types and sharing structural and functional features. Based on structural and functional considerations, MMPs have been classified into different families and subfamilies as follows: collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9), metalloelastases (MMP-12), the MT-MMPs (MMP-14, -15, -16, -17, -24 and 25), matrylsins (MMP-7 and -26), stromelysins (MMP-3, -10 and -11) and sheddases such as TNF-converting enzymes (TACEand ACE) (Akhavan et al., 2011; El-Meghawry El-Kenawy et al., 2006; Murphy and Nagase, 2008; Mott and Werb, 2004).

MATRIX METALLOPROTEINASES ROLES

MMPs function is to catalyze the breakdown of connective tissues extracellular matrix proteins by their ability to hydrolyze various components of tissue or matrix (Fage-McCaw et al., 2007; Ra and Parks, 2007). They are also involved in cleavage of cell surface receptors,
growth factors, cell-adhesion molecules, cytokines and chemokines, as well as other MMPs and unrelated proteases. Furthermore, MMPs are thought to play a major role in processes including cell-proliferation, differentiation and migration (adhesion/dispersion), angiogenesis, apoptosis and host defense (Hu et al., 2007; Kamel et al., 2009; Gupta and Kumaran, 2006a).

Apart from their role in degrading connective tissue, over-expression or over-activation of an MMP, or an imbalance between an MMP and a natural (i.e., endogenous) Tissue Inhibitor of a Matrix Metallo Proteinase (TIMP) has been linked to a pathogenesis of diseases characterized by the breakdown of connective tissue or extracellular matrix (Nagase et al., 2006; Pingleton, 2007; Gupta and Kumaran, 2006b).

**MATRIX METALLOPROTEINASES AND MULTIPLE SCLEROSIS**

Recent evidence indicates the contribution of MMPs to the pathogenesis of Multiple Sclerosis (MS) and its animal model, Experimental Autoimmune Encephalomyelitis (EAE) (Leppert et al., 2001; Nikfar et al., 2010). This evidence is based in part on the observation that all important effector cells potentially involved in the pathogenesis of EAE, such as T-lymphocytes, macrophages, astrocytes and microglial cells, apparently express different MMPs (Bar-Or et al., 2003; Elahi, 2011; Miabi et al., 2010).

Increased levels of MMP-9 were detected in the CSF of rodents with EAE. MMP-7 and -9 were considerably increased at the advanced phase of EAE. The administration of MMP-9 and MMP-2 resulted in breakdown of the Blood Brain Barrier (BBB) (Rosenberg 2002; Dressel et al., 2007).

In another study, it was demonstrated that when MMP-7, -8 and -9 were injected into the brain parenchyma of rats in an EAE model, leukocyte recruitment and BBB breakdown were observed (Rosenberg, 2009; Yang and Rosenberg, 2011).

Leppert et al. (2001) presented that MMP-9 enhanced trans basement membrane migration of T-lymphocytes. Recent evidence showed that expressed MMPs at the BBB and their corresponding ligands present on immune cells are of major importance for the transendothelial migration of T-cells across the BBB (Yang et al., 2011). Previous studies confirmed that these T cell migrations from BBB play essential role in organ-specific autoaggression (Persidsky, 1999; Clemons et al., 2005).

The myelin is another potential target for proteolytic MMPs, since these MMP proteases cleave myelin basic protein into immunodominant and encephalitogenic fragments (Zhao et al., 2010; Walker and Rosenberg, 2010). Thus, gelatinase would act as immediate effector molecules in the process of demyelination and could perpetuate the immunoinflammatory response. Therefore, it seems that gelatinase is the main mediator in the evolution of autoimmune CNS demyelination.

The study suggested that pathological hallmarks of multiple sclerosis are associated with overexpression of gelatinase, or a lack of their natural tissue inhibitors.

The evidence for the functional involvement of MMPs in the MS makes them attractive targets for therapeutical intervention.

**RATIONALES FOR THE HYPOTHESIS**

Different natural inhibitors and inhibitory mechanisms of metalloproteinases have been identified. The major inhibitors are Tissue Inhibitors of Metalloproteinases (TIMPs) whose primary function is to limit the degradative actions of the MMPs and be involved in myelination promoting effects (Clark et al., 2007; Nagase and Murphy, 2008; Ao et al., 2008).
Four TIMPs, numbered TIMP-1 through TIMP-4 based on their order of discovery have been identified in mammals Table 1 (Brew et al., 2000). Among the four TIMPs, TIMP-3 has the broadest inhibition spectrum as it inhibits several members of the metalloproteases especially the gelatinases (Kashiwagi et al., 2001; Wang et al., 2006).

Irrespective of effects on MMPs, TIMP’s ability to confer neuroprotection against excitotoxic injury or neural damage in nervous system (Chen et al., 2009) has potential clinical relevance, making TIMP regulation in multiple sclerosis of even greater interest.

It will be possible to design TIMP-3 with selective specificities for the gelatinases based on recent evidences for the TIMP (Nagase and Brew, 2003; Hamze et al., 2007). Therefore, it has been proposed that such “Designer TIMP-3” may be valuable for gene therapy of Multiple sclerosis.

CONCLUSION

Individual TIMPs differ in their efficacy for various MMPs. TIMP-3 possesses exclusive properties that set it apart from other family members. While all TIMPs are secreted into the extracellular space, TIMP-3 binds tightly to the extracellular matrix, suggesting that its actions are localised to the cell surface. Therefore, it may limit proteolytic damage to the extracellular matrix. The inhibitory effects of TIMP-3 on gelatinase also reduce proteolytic disruption of the BBB and lymphocyte recruitment into the brain that represent a critical event in disease pathogenesis of multiple sclerosis. Finally, our hypothesis proposes that, the natural gelatinase inhibitor, TIMP-3 possess proteinase inhibitory properties that may be exploited for therapeutic benefit in pathology of multiple sclerosis.

ACKNOWLEDGMENT

This research is based on current project and has been supported by Tehran and Golestan University of Medical Sciences, Iran.

REFERENCES


